Values First Advisors’s Immunovant IMVT Stock Holding History

Values First Advisors’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-6,962	Closed	-$108K	–	241
2023 Q1	$108K	Sell	6,962 -4,884	-41%	-$84.8K	0.07%	166
2022 Q4	$210K	Sell	11,846 -11,399	-49%	-$144K	0.15%	128
2022 Q3	$130K	Buy	23,245 +763	+3%	+$3.73K	0.09%	140
2022 Q2	$88K	Buy	22,482 +9,013	+67%	+$38.9K	0.06%	145
2022 Q1	$74K	Buy	13,469 +2,590	+24%	+$16.1K	0.05%	156
2021 Q4	$93K	Sell	10,879 -440	-4%	-$3.63K	0.06%	162
2021 Q3	$98K	Buy	+11,319	New	+$102K	0.06%	138

Other funds holding IMVT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Values First Advisors's IMVT Position: Q2 2023 in Review

Values First Advisors sold out of Immunovant (IMVT) in Q2 2023, closing a stake of 6,962 shares — an estimated $108K sold.

Values First Advisors first reported a position in IMVT in Q3 2021 and held it in 7 quarters. The position peaked at $210K in Q4 2022. 147 funds tracked by Wall St. Rank hold IMVT as of Q2 2023.

Values First Advisors reported no remaining Immunovant position as of Q2 2023 after selling out during the quarter.
Values First Advisors sold 6,962 Immunovant shares in Q2 2023, an estimated $108K.
Values First Advisors first reported a position in Immunovant in Q3 2021 and held it in 7 quarters.
Values First Advisors's Immunovant position peaked at $210K in Q4 2022.
147 funds tracked by Wall St. Rank held Immunovant as of Q2 2023.

Based on Values First Advisors's 13F filing for Q2 2023, filed 2 Aug 2023.